Related Experiment Video
Updated: Sep 26, 2025

Bio-energetics Investigation of Candida albicans Using Real-time Extracellular Flux Analysis
Published on: March 19, 2019
COVID-19 and Plethora of Fungal Infections
1Department of Cytology and Gynecological Pathology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
Purpose Of Review:
Severe-acute respiratory coronavirus 2 (SARS-CoV-2) causing corona virus disease 2019 (COVID-19) has been the single most important pathogen driving health care delivery system for the last one and half years. Now, as the time is passing, many issues related to co-infections/secondary infections/superinfections in COVID-19 patients are emerging. The literature is getting enriched everyday by addition of reports from all over the world for the same. The purpose of this review is to decipher the plethora of fungal infections in COVID-19.
Recent Findings:
COVID-19 infection along with it brought many risk factors namely lung injury, immunosuppression, need for oxygen therapy, monoclonal antibodies, steroid therapy, etc. which are known predisposing factors for fungal infections. Rather the extent and severity of fungal pathogens has been so much that it has led to new terminologies like CAC (COVID-19-associated Candida), CAPA (COVID-19-associated pulmonary aspergillosis) and CAM (COVID-19-associated mucormycosis). There is increase in invasiveness of Candida, prevalence of aspergillosis in COVID-19 damaged lung and outbreak of mucormycosis in COVID-19 patients resulting in "double trouble," keeping laboratory personnel, clinicians, and intensivists on their toes in managing these patients.
Summary:
Awareness and understanding regarding these possible complications is necessary to decrease the morbidity and mortality among patients. The COVID-19 and fungal coinfections may bring more insight into ways of pathogenesis of fungal infections, need for better antifungal agents, quick diagnostic modalities, and better management policies in the near future.
Insights
COVID-19 patients face increased risks of fungal co-infections, including invasive candidiasis, aspergillosis, and mucormycosis. Understanding these complications is crucial for reducing patient morbidity and mortality.
Area of Science:
- * Infectious Diseases
- * Mycology
- * Critical Care Medicine
Background:
- * Severe-acute respiratory coronavirus 2 (SARS-CoV-2) causing COVID-19 has significantly impacted healthcare systems.
- * COVID-19 presents risk factors for fungal infections such as lung injury, immunosuppression, and treatments like steroids and oxygen therapy.
- * Emerging fungal co-infections in COVID-19 patients include COVID-19-associated Candida (CAC), COVID-19-associated pulmonary aspergillosis (CAPA), and COVID-19-associated mucormycosis (CAM).
Purpose of the Study:
- * To review and analyze the spectrum of fungal infections occurring in COVID-19 patients.
- * To highlight the increased prevalence and severity of fungal pathogens in the context of COVID-19.
- * To emphasize the need for heightened awareness and understanding of these co-infections.
Main Methods:
- * This is a review article, synthesizing existing literature on fungal co-infections in COVID-19.
- * Data was compiled from global reports and scientific literature.
- * Analysis focused on identifying trends, risk factors, and clinical implications of fungal infections in COVID-19.
Main Results:
- * COVID-19 creates a conducive environment for fungal infections due to host-related factors and medical interventions.
- * Significant increases in invasive candidiasis, pulmonary aspergillosis, and mucormycosis outbreaks have been observed in COVID-19 patients.
- * These co-infections pose a "double trouble" scenario, complicating patient management and increasing healthcare burden.
Conclusions:
- * Increased awareness and understanding of fungal co-infections in COVID-19 are essential for improving patient outcomes.
- * Further research is needed to elucidate the pathogenesis of these co-infections.
- * Development of rapid diagnostic tools, effective antifungal agents, and refined management strategies are critical for the future.
Related Concept Videos
Fungal Phylum Microsporidia
Fungal Group Zygomycota
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Pulmonary Tuberculosis I
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Overview of Fungi
Factors Affecting the Risk of Infection
The integrity and count of the white blood cells help the body resist pathogens and fight infection. When impaired, it reduces the body's resistance to pathogens. The acidic pH levels of the gastrointestinal, genitourinary tracts, and skin...

